subject
Health, 10.03.2020 04:46 jlink6836

A 46-year-old man is currently enrolled in a Phase 2 study of a drug for severe diabetic neuropathy. While the study is on-going, a new drug becomes commercially available that may have equal or greater benefit to the subject. The investigator should do which of the following?
(A) Tell the subject about the new drug but discourage him from switching treatment until the study is completed.
(B) Withhold this information to avoid confusing the subject with other treatment options or alternatives.
(C) Give the subject comprehensive information about the new drug, including its side effects. Discuss the pros and cons of both investigational drug and commercially available drug and then allow the subject to decide whether to withdraw from the research to take the new drug.
(D) Don't tell the subject about the new drug since phycian have the right to try our new treatments with their new patients.

ansver
Answers: 3

Other questions on the subject: Health

image
Health, 21.06.2019 21:30, cravetyler3989
What is the targeted temp during acls
Answers: 2
image
Health, 22.06.2019 05:30, winterblackburn78
Brainliest. what are two not needed parts of the body?
Answers: 2
image
Health, 22.06.2019 13:30, glamourgirlno1foev
List three reasons people may begin using tobacco
Answers: 1
image
Health, 22.06.2019 21:50, Kimb6863
Insulin is a peptide therapeutic used to manage type 1 diabetes, which affects more than 20 million people worldwide according to the international diabetes federation. a significant limitation to the broad distribution and use of insulin to treat type 1 diabetes is the fact that it must be administered by injection rather than orally. why is insulin administered by injection and not orally?
Answers: 1
You know the right answer?
A 46-year-old man is currently enrolled in a Phase 2 study of a drug for severe diabetic neuropathy....

Questions in other subjects:

Konu
Geography, 11.03.2020 04:30